Cargando…

Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin

BACKGROUND: The xanthophyll astaxanthin is a high-value compound with applications in the nutraceutical, cosmetic, food, and animal feed industries. Besides chemical synthesis and extraction from naturally producing organisms like Haematococcus pluvialis, heterologous biosynthesis in non-carotenogen...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemuth, Karin, Steuer, Kristin, Albermann, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111352/
https://www.ncbi.nlm.nih.gov/pubmed/21521516
http://dx.doi.org/10.1186/1475-2859-10-29
_version_ 1782205609935896576
author Lemuth, Karin
Steuer, Kristin
Albermann, Christoph
author_facet Lemuth, Karin
Steuer, Kristin
Albermann, Christoph
author_sort Lemuth, Karin
collection PubMed
description BACKGROUND: The xanthophyll astaxanthin is a high-value compound with applications in the nutraceutical, cosmetic, food, and animal feed industries. Besides chemical synthesis and extraction from naturally producing organisms like Haematococcus pluvialis, heterologous biosynthesis in non-carotenogenic microorganisms like Escherichia coli, is a promising alternative for sustainable production of natural astaxanthin. Recent achievements in the metabolic engineering of E. coli strains have led to a significant increase in the productivity of carotenoids like lycopene or β-carotene by increasing the metabolic flux towards the isoprenoid precursors. For the heterologous biosynthesis of astaxanthin in E. coli, however, the conversion of β-carotene to astaxanthin is obviously the most critical step towards an efficient biosynthesis of astaxanthin. RESULTS: Here we report the construction of the first plasmid-free E. coli strain that produces astaxanthin as the sole carotenoid compound with a yield of 1.4 mg/g cdw (E. coli BW-ASTA). This engineered E. coli strain harbors xanthophyll biosynthetic genes from Pantoea ananatis and Nostoc punctiforme as individual expression cassettes on the chromosome and is based on a β-carotene-producing strain (E. coli BW-CARO) recently developed in our lab. E. coli BW-CARO has an enhanced biosynthesis of the isoprenoid precursor isopentenyl diphosphate (IPP) and produces β-carotene in a concentration of 6.2 mg/g cdw. The expression of crtEBIY along with the β-carotene-ketolase gene crtW148 (NpF4798) and the β-carotene-hydroxylase gene (crtZ) under controlled expression conditions in E. coli BW-ASTA directed the pathway exclusively towards the desired product astaxanthin (1.4 mg/g cdw). CONCLUSIONS: By using the λ-Red recombineering technique, genes encoding for the astaxanthin biosynthesis pathway were stably integrated into the chromosome of E. coli. The expression levels of chromosomal integrated recombinant biosynthetic genes were varied and adjusted to improve the ratios of carotenoids produced by this E. coli strain. The strategy presented, which combines chromosomal integration of biosynthetic genes with the possibility of adjusting expression by using different promoters, might be useful as a general approach for the construction of stable heterologous production strains synthesizing natural products. This is the case especially for heterologous pathways where excessive protein overexpression is a hindrance.
format Online
Article
Text
id pubmed-3111352
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31113522011-06-10 Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin Lemuth, Karin Steuer, Kristin Albermann, Christoph Microb Cell Fact Research BACKGROUND: The xanthophyll astaxanthin is a high-value compound with applications in the nutraceutical, cosmetic, food, and animal feed industries. Besides chemical synthesis and extraction from naturally producing organisms like Haematococcus pluvialis, heterologous biosynthesis in non-carotenogenic microorganisms like Escherichia coli, is a promising alternative for sustainable production of natural astaxanthin. Recent achievements in the metabolic engineering of E. coli strains have led to a significant increase in the productivity of carotenoids like lycopene or β-carotene by increasing the metabolic flux towards the isoprenoid precursors. For the heterologous biosynthesis of astaxanthin in E. coli, however, the conversion of β-carotene to astaxanthin is obviously the most critical step towards an efficient biosynthesis of astaxanthin. RESULTS: Here we report the construction of the first plasmid-free E. coli strain that produces astaxanthin as the sole carotenoid compound with a yield of 1.4 mg/g cdw (E. coli BW-ASTA). This engineered E. coli strain harbors xanthophyll biosynthetic genes from Pantoea ananatis and Nostoc punctiforme as individual expression cassettes on the chromosome and is based on a β-carotene-producing strain (E. coli BW-CARO) recently developed in our lab. E. coli BW-CARO has an enhanced biosynthesis of the isoprenoid precursor isopentenyl diphosphate (IPP) and produces β-carotene in a concentration of 6.2 mg/g cdw. The expression of crtEBIY along with the β-carotene-ketolase gene crtW148 (NpF4798) and the β-carotene-hydroxylase gene (crtZ) under controlled expression conditions in E. coli BW-ASTA directed the pathway exclusively towards the desired product astaxanthin (1.4 mg/g cdw). CONCLUSIONS: By using the λ-Red recombineering technique, genes encoding for the astaxanthin biosynthesis pathway were stably integrated into the chromosome of E. coli. The expression levels of chromosomal integrated recombinant biosynthetic genes were varied and adjusted to improve the ratios of carotenoids produced by this E. coli strain. The strategy presented, which combines chromosomal integration of biosynthetic genes with the possibility of adjusting expression by using different promoters, might be useful as a general approach for the construction of stable heterologous production strains synthesizing natural products. This is the case especially for heterologous pathways where excessive protein overexpression is a hindrance. BioMed Central 2011-04-26 /pmc/articles/PMC3111352/ /pubmed/21521516 http://dx.doi.org/10.1186/1475-2859-10-29 Text en Copyright ©2011 Lemuth et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Lemuth, Karin
Steuer, Kristin
Albermann, Christoph
Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin
title Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin
title_full Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin
title_fullStr Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin
title_full_unstemmed Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin
title_short Engineering of a plasmid-free Escherichia coli strain for improved in vivo biosynthesis of astaxanthin
title_sort engineering of a plasmid-free escherichia coli strain for improved in vivo biosynthesis of astaxanthin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111352/
https://www.ncbi.nlm.nih.gov/pubmed/21521516
http://dx.doi.org/10.1186/1475-2859-10-29
work_keys_str_mv AT lemuthkarin engineeringofaplasmidfreeescherichiacolistrainforimprovedinvivobiosynthesisofastaxanthin
AT steuerkristin engineeringofaplasmidfreeescherichiacolistrainforimprovedinvivobiosynthesisofastaxanthin
AT albermannchristoph engineeringofaplasmidfreeescherichiacolistrainforimprovedinvivobiosynthesisofastaxanthin